Abstract:Acute respiratory distress syndrome (ARDS) is an inflammatory lung disease with a high morbidity and mortality rate, for which no pharmacologic treatment is currently available. Our previous studies discovered that a pivotal step in the disease process is the activation of the nuclear factor of activated T cells (NFAT) c3 in lung macrophages, suggesting that inhibitors against the upstream protein phosphatase calcineurin should be effective for prevention/treatment of ARDS. Herein, we report the development of a highly potent, cell-permeable, and metabolically stable peptidyl inhibitor, CNI103, which selectively blocks the interaction between calcineurin and NFATc3, through computational and medicinal chemistry. CNI103 specifically inhibited calcineurin signaling in vitro and in vivo and exhibited a favorable pharmacokinetic profile, broad tissue distribution following different routes of administration, and minimal toxicity. Our data indicate that CNI103 is a promising novel treatment for ARDS and other inflammatory diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01236?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01236</a>.Table of additional acyl groups subjected to in silico screening and their calculated binding energies to calcineurin; table of sequences of hit peptides from OBOC library screening; table of stability of CNI103 upon incubation with mouse hepatocytes; tables of stability of CNI103 in simulated gastric fluid, intestinal fluid, and mouse liver microsomes; table of plasma concentration of CNI103 at different time points; structure and synthesis of OBOC peptide library; representative MALDI-TOF mass spectra of peptides derived from hit beads; representative binding curves of FITC-labeled peptides 13, 14, 16, and 19; turbidity test; effect of CN inhibitors on cell viability; effect of CNI93 on recruitment of neutrophils into lungs, on pulmonary function, on mouse body weight, and on the phosphatase activity of GST-CN toward p-nitrophenyl phosphate; CNI95 lacking ex vivo efficacy in prevention of LPS-induced cytokine production; intracellular stability of CNI103 in HCT116 cells; biodistribution of CNI103 in mice; selective uptake of CNI103Cy5 into immune cell subsets in vivo; ALI parameters in mice 24 h after LPS challenge; dose response of CNI103 for prevention of LPS-induced ALI; quantitation of TNFα levels in lung and kidney tissues of mice; and analytical HPLC tracings and MS data of peptides (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01236/suppl_file/jm0c01236_si_001.pdf">PDF</a>)Molecular formula strings of peptides (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01236/suppl_file/jm0c01236_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Cyclic Peptide Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury

Discovery of novel 5-phenyl-1H-pyrrole-2-carboxylic acids as Keap1-Nrf2 inhibitors for acute lung injury treatment

Structure-based molecular hybridization design of Keap1-Nrf2 inhibitors as novel protective agents of acute lung injury

Fragment-Based Discovery of Azocyclic Alkyl Naphthalenesulfonamides as Keap1-Nrf2 Inhibitors for Acute Lung Injury Treatment

Discovery of Propionic Acid Derivatives with a 5-THIQ Core as Potent and Orally Bioavailable Keap1-Nrf2 Protein-Protein Interaction Inhibitors for Acute Kidney Injury

Modified Peptide Inhibitors of the Keap1–Nrf2 Protein–Protein Interaction Incorporating Unnatural Amino Acids

Design, Synthesis, and Structure–Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein–Protein Interaction Inhibitors

An Exceptionally Potent Inducer of Cytoprotective Enzymes

A Peptidyl Inhibitor that Blocks Calcineurin–NFAT Interaction and Prevents Acute Lung Injury

Structure-Guided Conformational Restriction Leading to High-Affinity, Selective, and Cell-Active Tetrahydroisoquinoline-Based Noncovalent Keap1-Nrf2 Inhibitors

Design and synthesis optimization of novel diimide indoles derivatives for ameliorating acute lung injury through modulation of NF-κB signaling pathway

Chemical Evolution and Biological Evaluation of Natural Products for Efficient Therapy of Acute Lung Injury

A Novel Cell-Based Assay for Dynamically Detecting Neutrophil Extracellular Traps-Induced Lung Epithelial Injuries

Targeting Keap1 with Inulae Herba activated the Nrf2 receptor to alleviate LPS-mediated acute lung injury

A novel colchicine-myricetin heterozygous molecule: design, synthesis, and effective evaluations on the pathological models of acute lung injury in vitro and in vivo

Evidence that a Novel Chalcone Derivative, Compound 27, Acts on the Epithelium Via the PI3K/AKT/Nrf2-Keap1 Signaling Pathway, to Mitigate LPS-Induced Acute Lung Injury in Mice

Inhibition of Cathepsin L Ameliorates Inflammation Through the A20/NF-κB Pathway in Endotoxin-Induced Acute Lung Injury

Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction

Fluorous‐Tagged Peptide Nanoparticles Ameliorate Acute Lung Injury via Lysosomal Stabilization and Inflammation Inhibition in Pulmonary Macrophages

Structure-activity relationships of 1,4-bis(arylsulfonamido)-benzene or naphthalene-N,N'-diacetic acids with varying C2-substituents as inhibitors of Keap1-Nrf2 protein-protein interaction

Nebulized Inhalation of Peptide-Modified DNA Origami To Alleviate Acute Lung Injury